Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma.

McLean LS, et al. Drugs Aging. 2024;41(3):271-281.

What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper.

Loh KP, et al. J Oncol Pract. 2018;14(2):85-94.

American Geriatrics Society position statement: Making medical treatment decisions for unrepresented older adults.

Dixon JD, et al. J Am Geriatr Soc. 2025;73(5):1353-1364.

Immune-related adverse events of immune checkpoint inhibitors: a review.

Yin Q, et al. Front Immunol. 2023;14:1167975.

Recent advances in the diagnosis and management of high-risk cutaneous squamous cell carcinoma.

Dessinioti C, et al. Cancers (Basel). 2022;14(14):3556.

Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma.

Karia PS, et al. J Clin Oncol. 2014;32(4):327-34.

Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma.

Rischin D, et al. N Engl J Med. 2025;393(8):774-785.

Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT).

Koyfman SA, et al. J Clin Oncol. 2025;43(16 suppl):6000.

Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.

Claveau J, et al. Curr Oncol. 2020;27(4):e399-e407.

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.

Hughes BGM, et al. J Am Acad Dermatol. 2025;92(1):68-77.

Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.

Munoz-Couselo E, et al. J Clin Oncol. 2024;42(16suppl):9554.

Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.

Ruiz ES, et al. J Am Acad Dermatol. 2026;94(1):48-56.

Neoadjuvant cemiplimab for stage ii to iv cutaneous squamous-cell carcinoma.

Gross ND, et al. N Engl J Med. 2022;387:1557-1568.